278 related articles for article (PubMed ID: 29170919)
41. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
Baugh SDP
Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda.
Baseke J; Musenero M; Mayanja-Kizza H
Afr Health Sci; 2015 Jun; 15(2):322-7. PubMed ID: 26124775
[TBL] [Abstract][Full Text] [Related]
44. On the sexual transmission dynamics of hepatitis B virus in China.
Zou L; Ruan S; Zhang W
J Theor Biol; 2015 Mar; 369():1-12. PubMed ID: 25596515
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology and prevention of hepatitis B virus infection in China.
Lu FM; Li T; Liu S; Zhuang H
J Viral Hepat; 2010 Mar; 17 Suppl 1():4-9. PubMed ID: 20586928
[TBL] [Abstract][Full Text] [Related]
47. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study.
Liu J; Zhang S; Wang Q; Shen H; Zhang M; Zhang Y; Yan D; Liu M
Lancet Infect Dis; 2016 Jan; 16(1):80-86. PubMed ID: 26268687
[TBL] [Abstract][Full Text] [Related]
48. Epidemiological and clinical characteristics of hepatitis B virus in HIV-infected patients in Guangdong, China.
Huang SM; Cai WP; Hu FY; Lan Y; Liao BL; Chen YP; Tang XP
Int J STD AIDS; 2016 Sep; 27(10):890-7. PubMed ID: 26384940
[TBL] [Abstract][Full Text] [Related]
49. Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
Sagoe KW; Duedu KO; Ziga F; Agyei AA; Adiku TK; Lartey M; Mingle JA; Arens M
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):38. PubMed ID: 27251610
[TBL] [Abstract][Full Text] [Related]
50. Toward elimination and eradication of hepatitis B.
Chen DS
J Gastroenterol Hepatol; 2010 Jan; 25(1):19-25. PubMed ID: 20136972
[TBL] [Abstract][Full Text] [Related]
51. Control and Eradication Strategies of Hepatitis B Virus.
Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
[TBL] [Abstract][Full Text] [Related]
52. Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation--an insight from human immunodeficiency virus/hepatitis B virus coinfection.
Mondal RK; Khatun M; Ghosh S; Banerjee P; Datta S; Sarkar S; Saha B; Santra A; Banerjee S; Chowdhury A; Datta S
Clin Microbiol Infect; 2015 Jul; 21(7):710.e11-20. PubMed ID: 25882358
[TBL] [Abstract][Full Text] [Related]
53. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
[TBL] [Abstract][Full Text] [Related]
54. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
55. [Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication].
Pol S; Driss F; Carnot F; Michel ML; Berthelot P; Brechot C
C R Acad Sci III; 1993 Jul; 316(7):688-91. PubMed ID: 8019891
[TBL] [Abstract][Full Text] [Related]
56. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
Luo Q; Zhong Y; Yang Y; Xiong Q; Hu Z; Lu W; Huang P; Zhang N
J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
[TBL] [Abstract][Full Text] [Related]
57. Combination chemotherapy for hepatitis B virus: the path forward?
Shaw T; Locarnini S
Drugs; 2000 Sep; 60(3):517-31. PubMed ID: 11030464
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B Virus Infection: A Mini Review.
Asandem DA; Segbefia SP; Kusi KA; Bonney JHK
Viruses; 2024 May; 16(5):. PubMed ID: 38793606
[TBL] [Abstract][Full Text] [Related]
59. Epidemiology of hepatitis B and associated liver diseases in china.
Zhang Y; Zhang H; Elizabeth A; Liu XQ
Chin Med Sci J; 2013 Jan; 27(4):243-8. PubMed ID: 23294591
[TBL] [Abstract][Full Text] [Related]
60. Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study.
Wang X; Du Z; Wang Y; Wang J; Huang S; Wang Y; Gu J; Deng W; Gilmour S; Li J; Hao Y
J Epidemiol Glob Health; 2023 Sep; 13(3):517-527. PubMed ID: 37349664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
